On June 11, Rebecca Whitney announced she was stepping down as CEO of Highridge Medical to pursue “a new CEO opportunity outside the spine industry.” Three weeks later we learned where: Young Innovations, a dental products manufacturer owned by private equity firm TJC, named her chief executive on July 1. On paper, a routine executive transition. In practice, it deserves a closer read.
Whitney was not a hired gun. She spent eleven years inside the same spine franchise through four owners — Biomet, Zimmer Biomet, ZimVie, and finally H.I.G. Capital, which carved out ZimVie’s spine business in April 2024 and rebranded it Highridge. She was the continuity candidate, the executive who knew the franchise inside out. People like that don’t usually walk away from a private equity package two years into the hold period. Unless the math behind that package has changed.
Worth remembering: Whitney wasn’t even the first choice. At closing, H.I.G. announced Glen Kashuba as CEO, with Whitney as president. Barely a month later, Kashuba was moved to run EBI, the bone healing unit, and Whitney took the top job. Fourteen months after that, EBI itself was sold to Avista. Whatever the original plan looked like in the deal model, it didn’t survive contact with reality.
To be fair, the Whitney era produced genuine activity. Highridge shed EBI to focus purely on spine, picked up US rights to B.Braun’s activL lumbar disc, acquired the Accelus expandable-cage portfolio, and signed distribution agreements for PathKeeper navigation and, as recently as this April, Waypoint’s GPS pedicle system. It also landed one unambiguous win: UnitedHealthcare coverage for The Tether, effective April 2026 — a real door-opener for VBT.
Look closer, though, and a pattern emerges. Nearly everything on that list is distribution rights or bolt-on assets from smaller players. Capital-light moves. The company that promised at launch to double its R&D investment has announced no major organic platform since the carve-out. And since going private, Highridge has published no revenue figures at all — this from a business that was posting quarterly sales declines of 7-9% in its final year inside ZimVie, and which H.I.G. picked up for $375 million. In this industry, when a company stops talking about growth, the omission tends to be informative.
The tell, for me, is the destination. Whitney didn’t leave private equity; Young Innovations is PE-owned too. She didn’t leave for a bigger platform or a public company. She left spine entirely, after eleven years, for dental consumables. That looks like the decision of an executive who concluded that the exit she was building toward — a sale, an IPO, the payday that justifies carve-out life — was further away, or smaller, than it appeared in 2024.
Highridge, for its part, has named no successor three weeks on. Eric Major remains executive chairman, and if a strong internal candidate existed, we would probably know by now.
None of this means Highridge is in trouble. Nobody outside Westminster has the numbers, and the portfolio is real: Mobi-C remains one of the most widely implanted cervical discs worldwide, and The Tether just cleared its biggest reimbursement hurdle yet. But private equity holds run on clocks, and H.I.G. is entering year three. Watch what comes next — a new CEO with a turnaround résumé, further asset sales, or the quiet arrival of bankers. Any of the three will tell us more than the farewell posts did.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.